Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche CERA does not infringe EPO patents

Executive Summary

Final International Trade Commission ruling upholds earlier conclusion that Roche's investigational Continuous Erythropoietin Receptor Activator (CERA) anti-anemia drug "does not infringe any of Amgen's U.S. patents for epoetin," the company says Aug. 31. Amgen filed a complaint April 11 asking ITC to conduct an investigation into whether Roche is illegally importing pegylated recombinant human erythropoietin into the U.S. In July, an ITC administrative law judge determined that Roche's importation is subject to a clinical trial exemption from patent infringement. CERA is currently under development in the U.S. and EU for treatment of renal anemia in chronic kidney disease patients (1"The Pink Sheet" June 26, 2006, p. 17)...

You may also be interested in...

Amgen Expects At-Risk CERA Launch, But Says Swiss Gamble Won’t Pay Off

After failing to block the importation of pegylated erythropoietin, Amgen anticipates Roche will launch its continuous EPO receptor activator Mircera at risk

Roche To Build On Pharma, Diagnostics Expertise For Personalized Medicine

Roche sees its capabilities with both drug and diagnostics development as the key to maintaining a leadership position in targeted oncologics and personalized medicine

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts